Ventyx Biosciences, Inc. announced positive results from the Phase 2 trial of VTX002, a novel oral S1P1 receptor modulator, in patients with moderate-to-severely active ulcerative colitis (UC). The Phase 2 trial of V TX002 was a 13-week, randomized, double-blind, placebo-controlled, dose-ranging trial evaluating the efficacy and safety of two oral doses of VTX002 (30 mg and 60 mg once daily) in patients with moderate-to -severely active UC.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.75 USD | 0.00% | -7.72% | +11.34% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.34% | 194M | |
+14.84% | 121B | |
+18.31% | 112B | |
+2.94% | 22.72B | |
-18.26% | 20.82B | |
-18.47% | 16.66B | |
-42.36% | 16.36B | |
-14.23% | 16.19B | |
-0.68% | 13.17B | |
+21.87% | 11.11B |
- Stock Market
- Equities
- VTYX Stock
- News Ventyx Biosciences, Inc.
- Ventyx Biosciences Announces Positive Results from the Phase 2 Trial of VTX002 in Patients with Moderate-To-Severely Active Ulcerative Colitis